secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2026-08-06T12:15:17+00:00
Accession:  0001753926-26-001349
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical completes dosing of all 20 participants in Phase 1 trial of NPM-139 semaglutide implant
--------------------------------------------------------------------------------

- First 10 participants dosed July 29, 2026; remaining 10 dosed one week later; all insertions successful.
- Top-line data from the 20-participant SLIM-1 trial expected in November 2026.
- Trial includes low-dose NPM-139 and Wegovy comparator to assess safety, tolerability, PK, and weight change.
- Preclinical studies demonstrated sustainable 20% weight reduction in animal models.
- July 2026 agreement with Novo Nordisk to evaluate NPM-139 and NanoPortal implant technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626001349/0001753926-26-001349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626001349/vani-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001753926-26-001349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer